Cogent Biosciences Inc (NASDAQ:COGT)’s traded shares stood at 0.74 million during the last session, with the company’s beta value hitting 1.77. At the close of trading, the stock’s price was $8.74, to imply a decrease of -4.69% or -$0.43 in intraday trading. The COGT share’s 52-week high remains $12.61, putting it -44.28% down since that peak but still an impressive 38.56% since price per share fell to its 52-week low of $5.37. The company has a valuation of $965.43M, with an average of 1.71 million shares in intraday trading volume over the past 10 days and average of 1.62 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cogent Biosciences Inc (COGT), translating to a mean rating of 1.55. Of 4 analyst(s) looking at the stock, 0 analyst(s) give COGT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.58.
Cogent Biosciences Inc (NASDAQ:COGT) trade information
After registering a -4.69% downside in the last session, Cogent Biosciences Inc (COGT) has traded red over the past five days. The 5-day price performance for the stock is -6.12%, and 5.94% over 30 days. With these gigs, the year-to-date price performance is 12.05%. Short interest in Cogent Biosciences Inc (NASDAQ:COGT) saw shorts transact 9.35 million shares and set a 6.41 days time to cover.
The extremes give us $14 and $15 for target low and target high price respectively. As such, COGT has been trading -71.62% off suggested target high and -60.18% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 15.33% for the past 5-year period. While 2025 is set for a -0.39% return in earnings, projections for the next 5 years are at 10.60% annually.
COGT Dividends
Cogent Biosciences Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cogent Biosciences Inc (NASDAQ:COGT)’s Major holders
Cogent Biosciences Inc insiders hold 0.16% of total outstanding shares, with institutional holders owning 112.05% of the shares at 112.24% float percentage. In total, 112.05% institutions holds shares in the company, led by POINT72 ASSET MANAGEMENT, L.P.. As of 2024-06-30, the company held over 10.47 million shares (or 10.5506% of shares), all amounting to roughly $88.27 million.
The next major institution holding the largest number of shares is COMMODORE CAPITAL LP with 9.74 million shares, or about 9.8126% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $82.09 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Cogent Biosciences Inc (COGT) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 3.09 shares. This is just over 2.80% of the total shares, with a market valuation of $26.99 million. Data from the same date shows that the other fund manager holds a little less at 2.58, or 2.33% of the shares, all valued at about 22.51 million.
